These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31108884)

  • 1. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
    Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
    Molecules; 2019 May; 24(10):. PubMed ID: 31108884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
    Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
    Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer.
    Tang L; Wu W; Zhang C; Shi Z; Chen D; Zhai X; Jiang Y
    Bioorg Chem; 2021 Sep; 114():105026. PubMed ID: 34186467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability.
    Gurkan-Alp AS; Alp M; Karabay AZ; Koc A; Buyukbingol E
    Anticancer Agents Med Chem; 2020; 20(14):1728-1738. PubMed ID: 32357823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
    Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
    Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
    Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
    Tian Y; Xie Z; Liao C
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors.
    Chadha N; Jaggi AS; Silakari O
    Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
    Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
    Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity.
    Zhou J; Ji M; Yao H; Cao R; Zhao H; Wang X; Chen X; Xu B
    Org Biomol Chem; 2018 May; 16(17):3189-3202. PubMed ID: 29648554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.
    Zhou Y; Tang S; Chen T; Niu MM
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31766720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
    Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X
    Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
    Yu J; Luo L; Hu T; Cui Y; Sun X; Gou W; Hou W; Li Y; Sun T
    Eur J Med Chem; 2022 Jan; 227():113898. PubMed ID: 34656898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of 1H-benzo[d]imidazole-4-carboxamide PARP-1 inhibitors using different saturated nitrogen-contained heterocycle as linker group.
    Wu K; Peng X; Li Y; Chen M; Liu Y; Liu D; Jiang L; He Y; Peng J; Cao X
    Chem Biol Drug Des; 2023 Jun; 101(6):1335-1347. PubMed ID: 36752693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Lin C; Liu C; Hu P; Zou Z; Sun G
    Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.
    Velagapudi UK; Langelier MF; Delgado-Martin C; Diolaiti ME; Bakker S; Ashworth A; Patel BA; Shao X; Pascal JM; Talele TT
    J Med Chem; 2019 Jun; 62(11):5330-5357. PubMed ID: 31042381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors.
    Shen H; Ge Y; Wang J; Li H; Xu Y; Zhu Q
    Bioorg Med Chem Lett; 2021 Sep; 47():128169. PubMed ID: 34091044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.